Tirzepatide
And it appears that, as with GLP-1 analogs, there will be fast followers as future competition.
Still gonna be a great drug - the Social Security actuaries are going to have to break the badd nooze to the pols.
This is one of the uncommon, counterintuitive cases where a less selective agonist (or antagonist for that matter) that produces cross-talk with other receptors than just the main target is actually a bigg benefit. Sometimes 'side effects' can turn ~OUTT to be very, very good - as we found ~OUTT with the GLP-1 agonist analogs - which this drug kind of grew from - and is why I refer to it as a subclass, nott a totally different class than GLP-1 analogs.
A similar effect is seen with e.g., aspirin and ibuprofen versus Vioxx and other pure COX-2 inhibitors. Sometimes it is better for a drug to be less selective, which is the opposite of the normal expectation under the old 'settled science' dogma of pharmacology.
Market Data 
Markets 
